Detalhe da pesquisa
1.
A Toll pathway effector protects Drosophila specifically from distinct toxins secreted by a fungus or a bacterium.
Proc Natl Acad Sci U S A
; 120(12): e2205140120, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36917667
2.
The Toll pathway mediates Drosophila resilience to Aspergillus mycotoxins through specific Bomanins.
EMBO Rep
; 24(1): e56036, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36322050
3.
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.
Invest New Drugs
; 42(1): 127-135, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38270822
4.
Immune-Related Adverse Events in Patients with Lung Cancer.
Curr Oncol Rep
; 25(11): 1259-1275, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37782426
5.
High volatility of superbase-derived eutectic solvents used for CO2 capture.
Phys Chem Chem Phys
; 23(3): 2193-2210, 2021 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33439154
6.
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.
BMC Immunol
; 20(1): 43, 2019 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722672
7.
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Oncologist
; 24(11): e1148-e1155, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036771
8.
Sustainable wastewater treatment by deep eutectic solvents and natural silk for radioactive iodine capture.
Water Sci Technol
; 80(9): 1683-1691, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32039900
9.
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design.
BMC Genomics
; 19(1): 582, 2018 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30075702
10.
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Am J Hematol
; 96(10): E362-E367, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137072
11.
The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer.
Front Oncol
; 14: 1336546, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38476371
12.
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.
JCO Precis Oncol
; 8: e2300644, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38579193
13.
Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis.
Sci Rep
; 14(1): 2782, 2024 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307969
14.
Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.
Front Oncol
; 14: 1306311, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38384808
15.
Metastatic Non-Small Cell Lung Cancer Mimicking Metaplastic Breast Cancer: A Case Report.
JCO Precis Oncol
; 8: e2400027, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38905573
16.
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Res Sq
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38746220
17.
RefAI: a GPT-powered retrieval-augmented generative tool for biomedical literature recommendation and summarization.
J Am Med Inform Assoc
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38857454
18.
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy.
Cancers (Basel)
; 16(5)2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38473297
19.
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
JCO Precis Oncol
; 8: e2300555, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513170
20.
Trends in participant race and sex reporting in lung cancer phase III clinical trials.
Cancer Rep (Hoboken)
; 6 Suppl 1: e1856, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37421166